Exclusive: U.S. approval of Merck cancer immunotherapy expected soon
(Reuters) – U.S. regulators are likely to approve Merck & Co’s highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a
Read more